Secondary exposure-response analysis of DREAMM-6 Arm B and DREAMM-7 in relapsed/refractory multiple myeloma: higher belantamab mafodotin exposure with BVd was linked to better response without more grade ≥3 ocular events, favouring 2.5 over 1.9 mg/kg.
RCT
Papathanasiou et al. Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7